What is HC Wainwright's Estimate for PMVP FY2026 Earnings?

Key Points

• HC Wainwright cut its FY2026 EPS estimate for PMV Pharmaceuticals to ($1.35) from ($1.03), versus the broader consensus estimate of ($1.20). It maintained a Buy rating and a $5 price target.
• PMV reported quarterly EPS of ($0.52), missing analysts’ consensus estimate of ($0.34) by $0.18.
• Analyst sentiment is mixed but leans positive: MarketBeat lists a Moderate Buy consensus rating and a $4.33 average price target.

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) - Analysts at HC Wainwright lowered their FY2026 earnings estimates for PMV Pharmaceuticals in a report released on Wednesday, November 11th. HC Wainwright analyst R. Burns now expects that the company will earn ($1.35) per share for the year, down from their prior forecast of ($1.03). HC Wainwright currently has a "Buy" rating and a $5.00 target price on the stock. The consensus estimate for PMV Pharmaceuticals' current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PMV Pharmaceuticals' Q4 2026 earnings at ($0.21) EPS, Q1 2027 earnings at ($0.22) EPS, Q2 2027 earnings at ($0.23) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($0.83) EPS.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.18).

Several other analysts also recently commented on the stock. Weiss Ratings raised shares of PMV Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, September 24th. Wall Street Zen lowered PMV Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, PMV Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $4.33.

PMV Pharmaceuticals Trading Down 4.0%

PMVP opened at $1.21 on Friday. The stock has a market cap of $64.69 million, a price-to-earnings ratio of -0.79 and a beta of 1.52. The stock has a fifty day moving average price of $1.39 and a 200 day moving average price of $1.31. PMV Pharmaceuticals has a 1 year low of $1.02 and a 1 year high of $1.91.

Institutional Investors Weigh In On PMV Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Eversept Partners LP bought a new position in shares of PMV Pharmaceuticals in the first quarter valued at approximately $2,912,000. BlackRock Inc. acquired a new stake in shares of PMV Pharmaceuticals in the second quarter worth $1,233,000. Stonepine Capital Management LLC bought a new stake in shares of PMV Pharmaceuticals during the 2nd quarter worth $718,355. ADAR1 Capital Management LLC bought a new stake in shares of PMV Pharmaceuticals during the 2nd quarter worth $269,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of PMV Pharmaceuticals during the 2nd quarter worth $43,000. Institutional investors own 90.20% of the company's stock.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc. is a clinical-stage precision oncology company focused on developing therapies that target cancer-causing mutations in the tumor suppressor protein p53. The company aims to discover and develop small-molecule medicines designed to restore the normal tumor-suppressing function of mutant p53 proteins. PMV's lead product candidate is rezatapopt, also known as PC14586, an investigational oral therapy designed to selectively target the p53 Y220C mutation. This mutation occurs in a range of solid tumors, and rezatapopt is being evaluated for its potential to reactivate the altered p53 protein and inhibit cancer-cell growth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.